Akademska digitalna zbirka SLovenije - logo
VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
  • Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
    Sominanda, A. ...
    Development of neutralizing antibodies (NAbs) reduces the clinical efficacy ofinterferon beta (IFNbeta) treatment in multiple sclerosis (MS) patients. Theaim of this study was to evaluate NAb ... seroprevalence (frequency of patients with NAbs) and immunogenicity (titer levels) of IFNbeta preparations in a clinical setting. We analysed 1115 consecutive MS patients, treated with one of the three available IFNbeta preparations, for an average of 40 months (1-120 months), for the presence of NAbs with the MxA protein induction assay.Overall, 32% of patients were positive for NAbs with neutralizing titersabove 10. The frequency of NAbs, ie, the seroprevalence, was 13% in Avonex-treated patients, 43% for Betaferon, 39% for Rebif22 and 30% for Rebif44. In addition, the potential to induce high titer levels, ie, the immunogenicity, was observed to differ between preparations. Avonex, showing the lowest seroprevalence, also showed low immunogenicity and typically induced low titers. Betaferon, showing the highest seroprevalence when inducing NAbs, induced lower titers compared to Rebif22 and Rebif44. Treatmentduration over five years only marginally correlated with decreased seroprevalence and titer levels.In conclusion, NAbs to IFNbeta are common in aclinical setting and the IFNbeta preparations differ not only in NAb seroprevalence, but also in immunogenicity.
    Vir: Multiple sclerosis. - ISSN 1352-4585 (Letn. 13, št. 2, 2007, str. 208-214)
    Vrsta gradiva - članek, sestavni del
    Leto - 2007
    Jezik - angleški
    COBISS.SI-ID - 24547801
    DOI

vir: Multiple sclerosis. - ISSN 1352-4585 (Letn. 13, št. 2, 2007, str. 208-214)
loading ...
loading ...
loading ...

Vnos na polico